| |
Wednesday, February 12, 2025 | 10am ET / 7am PT If you are a company developing advanced therapies, don’t miss this webinar to learn about packaging innovations and aseptic filling solutions that meet the demands of emerging therapies and ensure product integrity, safety and efficiency.
|
|
|
Wednesday, February 19, 2025 | 11am ET / 8am PT This webinar takes a deep dive into effective formulation strategies to overcome current solubility and bioavailability hurdles. Join us to explore the latest advancements in bioavailability enhancement technologies and critical factors for selecting the right formulation approach. Register now.
|
|
| By Darren Incorvaia Jane Grogan, Ph.D., took over Biogen’s research department in the wake of large-scale layoffs. Now, a little more than a year later, she’s making cuts of her own. |
|
|
|
By Gabrielle Masson This year’s JP Morgan struck a different tone than previous years—a very pleasant one, despite higher security anxieties following the fatal shooting of UnitedHealthcare’s CEO in December. |
By Kevin Dunleavy An observational study from Washington University in St. Louis has shed more light on the benefits—as well as the risks—of using new diabetes and weight loss drugs from Novo Nordisk and Eli Lilly. According to the study, researchers found that use of the new medicines may reduce the risk of Alzheimer’s disease and substance abuse disorders while increasing the risk of digestive issues and arthritis. |
By Fraiser Kansteiner The FDA has slapped a warning letter on Sanofi’s Genzyme facility in Framingham, Massachusetts, after an inspection last summer uncovered issues around subpar manufacturing error investigations, inconsistent active pharmaceutical ingredient production, improper equipment and more. |
|
Thursday, February 20, 2025 | 1pm ET / 10am PT ALS remains one of the most complex neurological diseases to understand and treat. Join industry experts to learn about the latest advancements in ALS research, with exclusive insights into the latest scientific progress shaping the future of ALS therapies. Register now.
|
|
By Conor Hale Among his first actions as president, Donald Trump has rescinded an executive order signed during the Biden administration that directed the U.S. government to develop safeguards for the development of AI programs. |
By Angus Liu AstraZeneca and Daiichi Sankyo’s second antibody-drug conjugate, TROP2-directed Dato-Dxd, has crossed the U.S. regulatory finish line. |
By Gabrielle Masson “There's an evolution of our economic model that starts with IRA, and will get worse and worse and worse, but I think there's so many opportunities for us to counter that with new ways of working,” R&D head Andy Plump, M.D., Ph.D., told Fierce Biotech at the annual J.P. Morgan Healthcare Conference. |
By Nick Paul Taylor GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase eightfold in a decade as therapies address unmet medical need. |
By Darren Incorvaia A new study of nerve cells affected by Huntington’s disease reveals that the disease-causing gene slowly expands over time but doesn't start causing harm until it hits a toxic threshold that rapidly leads to the nerve cell’s death. |
By Joseph Keenan Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing Consortium aimed at pioneering new advances in how medicines are produced. |
Fierce podcastsDon’t miss an episode |
| | Jay Chaudary, former director of the Indiana Division of Mental Health and Addiction, led the effort to overhaul the state's behavioral health system. He takes listeners through lessons learned and potential future policy threats to care access. |
|
|---|
|
|
|
Wednesday, February 26, 2025 | 1pm ET / 10am PT This webinar reveals how to harness their combined power to reach and engage your target audience, with actionable insights into how brands can leverage these emerging spaces in new ways. Register now.
|
|
| ResearchStudy shows significant Rx growth using new EHR marketing technique. Sponsored by: Veradigm |
| WhitepaperHow can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
| ResearchRead this case study to discover how programmatic EHR advertising can transform your omnichannel marketing strategy. Sponsored by: Veradigm |
| |
|
